The predictive value of the aCL and anti-β2GPI at the time of acute deep vein thrombosis—a two-year prospective study

Perdan-Pirkmajer, Katja (avtor), Žigon, Polona (avtor), Boc, Anja (avtor), Podovšovnik, Eva (avtor), Čučnik, Saša (avtor), Mavri, Alenka (avtor), Rotar, Žiga (avtor), Ambrožič, Aleš (avtor)

Antiphospholipid syndrome (APS) is an important cause of deep vein thrombosis (DVT). According to current APS classification criteria, APS cannot be confirmed until 24 weeks after DVT. This time frame results in frequent discontinuation of anticoagulant treatment before APS is diagnosed. Therefore, the aim of our study was to evaluate the potential predictive value of anticardiolipin (aCL) and anti-β2glycoprotein I (anti-β2GPI) before discontinuation of anticoagulation therapy. Patients with newly diagnosed DVT were included into a 24-month prospective study. All patients received anticoagulant therapy. aCL and anti-β2GPI were determined at inclusion and every four weeks for the first 24 weeks and then one and two years after inclusion. APS was confirmed in 24/221 (10.9%) patients. At the time of acute DVT 20/24 (83.3%), APS patients had positive aCL and/or anti-β2GPI. Two patients had low aCL levels and two were negative at the time of acute DVT but later met APS criteria due to lupus anticoagulant (LA). Our data indicate that negative aCL and/or anti-β2GPI at the time of acute DVT make further aPL testing unnecessary; however, LA should be determined after discontinuation of anticoagulant therapy. Positive aCL and/or anti-β2GPI at the time of acute DVT have a strong positive predictive value for APS and may support therapeutic decisions.

• Jezik: Angleški jezik
• Ključne besede: thrombosis, antiphospholipid syndrome, antiphospholipid antibodies, prediction
• Vrsta gradiva: Članek v reviji
• Tipologija: 1.01 - Izvirni znanstveni članek
• Organizacija: MF - Medicinska fakulteta ; FFA - Fakulteta za farmacijo
• Status publikacije: Objavljeno
• Različica publikacije: Objavljena publikacija
• Leto izida: 2021
• Št. strani: 10 str.
• Številčenje: Vol. 9, iss. 8, art. 901
• PID: 20.500.12556/RUL-135957
• UDK: 616.1
• ISSN pri članku: 2227-9059
• DOI: 10.3390/biomedicines9080901
• COBISS.SI-ID: 72525315
• Datum objave v RUL: 05.04.2022

Gradivo je del revije

• Naslov: Biomedicines
• Skrajšan naslov: Biomedicines
• Založnik: MDPI AG
• ISSN: 2227-9059
• COBISS.SI-ID: 523006745

Licence

• Licenca: CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
• Povezava: http://creativecommons.org/licenses/by/4.0/deed.sl
• Opis: To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
• Začetek licenciranja: 01.08.2021

Sekundarni jezik

• Jezik: Slovenski jezik
• Ključne besede: tromboza, antifosfolipidni sindrom, antifosfolipidna protitelesa

Projekti

• Financer: ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
• Številka projekta: P3-0314
• Naslov: Sistemske avtoimunske bolezni

• Financer: ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
• Številka projekta: J7-8276
• Naslov: Vpliv protirevmatičnih zdravil na inzulinsko rezistenco in energijsko presnovo v skeletni mišici